CommercialCoverageHigh impact
Commercial and Other Pharmacy Program October 1 Updates
Florida Blue·FL · Pharmacy, Cardiology, Rheumatology +7 more·Pharmacy
Effective date
Oct 1, 2026
We identified it
Sep 2, 2026
Summary
Florida Blue is implementing comprehensive pharmacy program changes effective October 1, 2026, affecting commercial plans. Changes include: (1) adding 80+ medications to the Responsible Quantity Program with specific dispensing limits, (2) adding medications to Step Therapy Program requirements, (3) excluding 30+ brand-name and generic drugs from coverage, and (4) requiring prior authorization for 30+ new medications. Billing teams must update systems to enforce quantity limits, apply step therapy logic, deny excluded medications, and require prior authorization before processing claims.
Action Required
By September 30, 2026: (1) Billing team must update pharmacy billing system to enforce Responsible Quantity Program limits for all 80+ added medications listed in the policy (e.g., Armlupeg 2 syringes/28 days, Auvelity 1 pack/180 days, tofacitinib citrate 10 mg 240 tabs/365 days). Claims exceeding these limits will be auto-denied. (2) Implement Step Therapy requirements: configure system to require generic duloxetine, Auvelity, Atoncy, and Bysanti to be tried first before covering brand alternatives for antidepressants and atypical antipsychotics. (3) Add 30+ medications to the pharmacy coverage exclusion list (Januvia, Xeljanz, Pomalyst, Opsumit, Farxiga, Mavenclad, Myrbetriq, and others) so claims automatically deny with messaging directing patients to covered therapeutic alternatives. (4) Implement prior authorization requirement for 30+ medications including Leqembi IQLIK, Saphnelo, Skyrizi, Uptravi, Wegovy HD, Zepbound Kwikpen, and all tofacitinib formulations—claims cannot process without pre-auth approval. (5) For Net Results formulary members specifically, add 35+ additional exclusions (Austedo, Briviact, Selarsdi, Ofev, and others). (6) Update claim adjudication rules to check all three programs (quantity limits, step therapy, prior auth) before payment. (7) Inform pharmacy staff and providers of changes to prevent claim delays and patient access issues.